Botulinum Toxin Neurotoxic Component For Treating Juvenile Cerebral Palsy

Abstract

The invention provides for the use of a presynaptic neurotoxin (for example a bacterial neurotoxin such as botulinum toxin A) for the manufacture of a medicament for the treatment of cerebral palsy in juvenile patients. The juvenile patients are preferably juveniles of up to 6 years in age.


Claims
Owners (US)
Download PDF
Document Preview
Document History
  • Publication: May 27, 2008
  • Application: May 22, 2007
    US US 75209607 A
  • Priority: May 22, 2007
    US US 75209607 A
  • Priority: Oct 29, 2004
    US US 97650704 A
  • Priority: May 22, 2002
    US US 15528002 A
  • Priority: Jun 27, 1994
    US US 21135294 A
  • Priority: Sep 16, 1992
    GB GB 9201697 W
  • Priority: Sep 24, 1991
    GB GB 9120306 A

Download Citation


Sign in to the Lens

Feedback